Application 021137
- Type
- NDA
- Sponsor
- GENUS LIFESCIENCES
Application Products#
| Product | Drug | Ingredient | Form | Strength | Reference drug | Reference standard |
|---|---|---|---|---|---|---|
| 001 | LEVOLET | LEVOTHYROXINE SODIUM | TABLET;ORAL | 0.025MG | No | No |
| 002 | LEVOLET | LEVOTHYROXINE SODIUM | TABLET;ORAL | 0.05MG | No | No |
| 003 | LEVOLET | LEVOTHYROXINE SODIUM | TABLET;ORAL | 0.075MG | No | No |
| 004 | LEVOLET | LEVOTHYROXINE SODIUM | TABLET;ORAL | 0.088MG | No | No |
| 005 | LEVOLET | LEVOTHYROXINE SODIUM | TABLET;ORAL | 0.1MG | No | No |
| 006 | LEVOLET | LEVOTHYROXINE SODIUM | TABLET;ORAL | 0.112MG | No | No |
| 007 | LEVOLET | LEVOTHYROXINE SODIUM | TABLET;ORAL | 0.125MG | No | No |
| 008 | LEVOLET | LEVOTHYROXINE SODIUM | TABLET;ORAL | 0.137MG | No | No |
| 009 | LEVOLET | LEVOTHYROXINE SODIUM | TABLET;ORAL | 0.15MG | No | No |
| 010 | LEVOLET | LEVOTHYROXINE SODIUM | TABLET;ORAL | 0.175MG | No | No |
| 011 | LEVOLET | LEVOTHYROXINE SODIUM | TABLET;ORAL | 0.2MG | No | No |
| 012 | LEVOLET | LEVOTHYROXINE SODIUM | TABLET;ORAL | 0.3MG | No | No |
Orange Book products#
| Application-product | Trade name | Ingredient | Strength | Dosage form / route | TE codes | RLD / RS | Approval date |
|---|---|---|---|---|---|---|---|
| N021137-001 | LEVOLET | LEVOTHYROXINE SODIUM | 0.025MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3,AB4 | 2003-06-06 | |
| N021137-002 | LEVOLET | LEVOTHYROXINE SODIUM | 0.05MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3,AB4 | 2003-06-06 | |
| N021137-003 | LEVOLET | LEVOTHYROXINE SODIUM | 0.075MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3,AB4 | 2003-06-06 | |
| N021137-004 | LEVOLET | LEVOTHYROXINE SODIUM | 0.088MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3,AB4 | 2003-06-06 | |
| N021137-005 | LEVOLET | LEVOTHYROXINE SODIUM | 0.1MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3,AB4 | 2003-06-06 | |
| N021137-006 | LEVOLET | LEVOTHYROXINE SODIUM | 0.112MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3,AB4 | 2003-06-06 | |
| N021137-007 | LEVOLET | LEVOTHYROXINE SODIUM | 0.125MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3,AB4 | 2003-06-06 | |
| N021137-008 | LEVOLET | LEVOTHYROXINE SODIUM | 0.137MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3,AB4 | 2003-06-06 | |
| N021137-009 | LEVOLET | LEVOTHYROXINE SODIUM | 0.15MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3,AB4 | 2003-06-06 | |
| N021137-010 | LEVOLET | LEVOTHYROXINE SODIUM | 0.175MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3,AB4 | 2003-06-06 | |
| N021137-011 | LEVOLET | LEVOTHYROXINE SODIUM | 0.2MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3,AB4 | 2003-06-06 | |
| N021137-012 | LEVOLET | LEVOTHYROXINE SODIUM | 0.3MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3,AB4 | 2003-06-06 |
Therapeutic equivalence codes#
| Application-product | TE code |
|---|---|
| N021137-001 | AB1 |
| N021137-001 | AB2 |
| N021137-001 | AB3 |
| N021137-001 | AB4 |
| N021137-002 | AB1 |
| N021137-002 | AB2 |
| N021137-002 | AB3 |
| N021137-002 | AB4 |
| N021137-003 | AB1 |
| N021137-003 | AB2 |
| N021137-003 | AB3 |
| N021137-003 | AB4 |
| N021137-004 | AB1 |
| N021137-004 | AB2 |
| N021137-004 | AB3 |
| N021137-004 | AB4 |
| N021137-005 | AB1 |
| N021137-005 | AB2 |
| N021137-005 | AB3 |
| N021137-005 | AB4 |
| N021137-006 | AB1 |
| N021137-006 | AB2 |
| N021137-006 | AB3 |
| N021137-006 | AB4 |
| N021137-007 | AB1 |
| N021137-007 | AB2 |
| N021137-007 | AB3 |
| N021137-007 | AB4 |
| N021137-008 | AB1 |
| N021137-008 | AB2 |
| N021137-008 | AB3 |
| N021137-008 | AB4 |
| N021137-009 | AB1 |
| N021137-009 | AB2 |
| N021137-009 | AB3 |
| N021137-009 | AB4 |
| N021137-010 | AB1 |
| N021137-010 | AB2 |
| N021137-010 | AB3 |
| N021137-010 | AB4 |
| N021137-011 | AB1 |
| N021137-011 | AB2 |
| N021137-011 | AB3 |
| N021137-011 | AB4 |
| N021137-012 | AB1 |
| N021137-012 | AB2 |
| N021137-012 | AB3 |
| N021137-012 | AB4 |
Orange Book patents#
| Application-product | Patent | Expiration | Use code | Coverage / status | Submission date |
|---|---|---|---|---|---|
| N021137-003 | 10231931 | 2038-03-23 | Drug product | 2022-01-07 | |
| N021137-003 | 10406108 | 2038-03-23 | Drug product | 2022-01-07 | |
| N021137-004 | 10231931 | 2038-03-23 | Drug product | 2022-01-07 | |
| N021137-004 | 10406108 | 2038-03-23 | Drug product | 2022-01-07 | |
| N021137-005 | 10231931 | 2038-03-23 | Drug product | 2022-01-07 | |
| N021137-005 | 10406108 | 2038-03-23 | Drug product | 2022-01-07 | |
| N021137-006 | 10231931 | 2038-03-23 | Drug product | 2022-01-07 | |
| N021137-006 | 10406108 | 2038-03-23 | Drug product | 2022-01-07 | |
| N021137-007 | 10231931 | 2038-03-23 | Drug product | 2022-01-07 | |
| N021137-007 | 10406108 | 2038-03-23 | Drug product | 2022-01-07 | |
| N021137-008 | 10231931 | 2038-03-23 | Drug product | 2022-01-07 | |
| N021137-008 | 10406108 | 2038-03-23 | Drug product | 2022-01-07 | |
| N021137-009 | 10231931 | 2038-03-23 | Drug product | 2022-01-07 | |
| N021137-009 | 10406108 | 2038-03-23 | Drug product | 2022-01-07 | |
| N021137-010 | 10231931 | 2038-03-23 | Drug product | 2022-01-07 | |
| N021137-010 | 10406108 | 2038-03-23 | Drug product | 2022-01-07 | |
| N021137-011 | 10231931 | 2038-03-23 | Drug product | 2022-01-07 | |
| N021137-011 | 10406108 | 2038-03-23 | Drug product | 2022-01-07 | |
| N021137-012 | 10231931 | 2038-03-23 | Drug product | 2022-01-07 | |
| N021137-012 | 10406108 | 2038-03-23 | Drug product | 2022-01-07 |
Observed Orange Book product history#
Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
| Captured | Edition | Application-product | Trade name | Strength | Dosage form / route | Product TE source text | RLD / RS | Approval date | Source SHA-256 |
|---|---|---|---|---|---|---|---|---|---|
| 2026-09-14 22:38:34 | 2026-08 | N021137-001 | LEVOLET | 0.025MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3,AB4 | 2003-06-06 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N021137-002 | LEVOLET | 0.05MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3,AB4 | 2003-06-06 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N021137-003 | LEVOLET | 0.075MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3,AB4 | 2003-06-06 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N021137-004 | LEVOLET | 0.088MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3,AB4 | 2003-06-06 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N021137-005 | LEVOLET | 0.1MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3,AB4 | 2003-06-06 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N021137-006 | LEVOLET | 0.112MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3,AB4 | 2003-06-06 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N021137-007 | LEVOLET | 0.125MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3,AB4 | 2003-06-06 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N021137-008 | LEVOLET | 0.137MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3,AB4 | 2003-06-06 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N021137-009 | LEVOLET | 0.15MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3,AB4 | 2003-06-06 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N021137-010 | LEVOLET | 0.175MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3,AB4 | 2003-06-06 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N021137-011 | LEVOLET | 0.2MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3,AB4 | 2003-06-06 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N021137-012 | LEVOLET | 0.3MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3,AB4 | 2003-06-06 | 84e616aacf4f… | |
| 2026-08-18 06:07:40 | 2026-07 | N021137-001 | LEVOLET | 0.025MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3,AB4 | 2003-06-06 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | N021137-002 | LEVOLET | 0.05MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3,AB4 | 2003-06-06 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | N021137-003 | LEVOLET | 0.075MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3,AB4 | 2003-06-06 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | N021137-004 | LEVOLET | 0.088MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3,AB4 | 2003-06-06 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | N021137-005 | LEVOLET | 0.1MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3,AB4 | 2003-06-06 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | N021137-006 | LEVOLET | 0.112MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3,AB4 | 2003-06-06 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | N021137-007 | LEVOLET | 0.125MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3,AB4 | 2003-06-06 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | N021137-008 | LEVOLET | 0.137MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3,AB4 | 2003-06-06 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | N021137-009 | LEVOLET | 0.15MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3,AB4 | 2003-06-06 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | N021137-010 | LEVOLET | 0.175MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3,AB4 | 2003-06-06 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | N021137-011 | LEVOLET | 0.2MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3,AB4 | 2003-06-06 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | N021137-012 | LEVOLET | 0.3MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3,AB4 | 2003-06-06 | caaa826d4ba7… | |
| 2026-02-19 14:30 UTC | 2026-02 | N021137-001 | LEVOLET | 0.025MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3,AB4 | 2003-06-06 | 011fe1cb6892… | |
| 2026-02-19 14:30 UTC | 2026-02 | N021137-002 | LEVOLET | 0.05MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3,AB4 | 2003-06-06 | 011fe1cb6892… | |
| 2026-02-19 14:30 UTC | 2026-02 | N021137-003 | LEVOLET | 0.075MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3,AB4 | 2003-06-06 | 011fe1cb6892… | |
| 2026-02-19 14:30 UTC | 2026-02 | N021137-004 | LEVOLET | 0.088MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3,AB4 | 2003-06-06 | 011fe1cb6892… | |
| 2026-02-19 14:30 UTC | 2026-02 | N021137-005 | LEVOLET | 0.1MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3,AB4 | 2003-06-06 | 011fe1cb6892… | |
| 2026-02-19 14:30 UTC | 2026-02 | N021137-006 | LEVOLET | 0.112MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3,AB4 | 2003-06-06 | 011fe1cb6892… | |
| 2026-02-19 14:30 UTC | 2026-02 | N021137-007 | LEVOLET | 0.125MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3,AB4 | 2003-06-06 | 011fe1cb6892… | |
| 2026-02-19 14:30 UTC | 2026-02 | N021137-008 | LEVOLET | 0.137MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3,AB4 | 2003-06-06 | 011fe1cb6892… | |
| 2026-02-19 14:30 UTC | 2026-02 | N021137-009 | LEVOLET | 0.15MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3,AB4 | 2003-06-06 | 011fe1cb6892… | |
| 2026-02-19 14:30 UTC | 2026-02 | N021137-010 | LEVOLET | 0.175MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3,AB4 | 2003-06-06 | 011fe1cb6892… | |
| 2026-02-19 14:30 UTC | 2026-02 | N021137-011 | LEVOLET | 0.2MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3,AB4 | 2003-06-06 | 011fe1cb6892… | |
| 2026-02-19 14:30 UTC | 2026-02 | N021137-012 | LEVOLET | 0.3MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3,AB4 | 2003-06-06 | 011fe1cb6892… | |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | N021137-001 | LEVOLET | 0.025MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3,AB4 | 2003-06-06 | 31067a03dcf5… | |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | N021137-002 | LEVOLET | 0.05MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3,AB4 | 2003-06-06 | 31067a03dcf5… | |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | N021137-003 | LEVOLET | 0.075MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3,AB4 | 2003-06-06 | 31067a03dcf5… | |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | N021137-004 | LEVOLET | 0.088MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3,AB4 | 2003-06-06 | 31067a03dcf5… |
Observed Orange Book normalized TE history#
| Captured | Edition | Application-product | TE code | Order | Source SHA-256 |
|---|---|---|---|---|---|
| 2026-09-14 22:38:34 | 2026-08 | N021137-001 | AB1 | 1 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | N021137-001 | AB2 | 2 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | N021137-001 | AB3 | 3 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | N021137-001 | AB4 | 4 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | N021137-002 | AB1 | 1 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | N021137-002 | AB2 | 2 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | N021137-002 | AB3 | 3 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | N021137-002 | AB4 | 4 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | N021137-003 | AB1 | 1 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | N021137-003 | AB2 | 2 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | N021137-003 | AB3 | 3 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | N021137-003 | AB4 | 4 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | N021137-004 | AB1 | 1 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | N021137-004 | AB2 | 2 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | N021137-004 | AB3 | 3 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | N021137-004 | AB4 | 4 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | N021137-005 | AB1 | 1 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | N021137-005 | AB2 | 2 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | N021137-005 | AB3 | 3 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | N021137-005 | AB4 | 4 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | N021137-006 | AB1 | 1 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | N021137-006 | AB2 | 2 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | N021137-006 | AB3 | 3 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | N021137-006 | AB4 | 4 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | N021137-007 | AB1 | 1 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | N021137-007 | AB2 | 2 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | N021137-007 | AB3 | 3 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | N021137-007 | AB4 | 4 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | N021137-008 | AB1 | 1 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | N021137-008 | AB2 | 2 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | N021137-008 | AB3 | 3 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | N021137-008 | AB4 | 4 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | N021137-009 | AB1 | 1 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | N021137-009 | AB2 | 2 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | N021137-009 | AB3 | 3 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | N021137-009 | AB4 | 4 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | N021137-010 | AB1 | 1 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | N021137-010 | AB2 | 2 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | N021137-010 | AB3 | 3 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | N021137-010 | AB4 | 4 | 84e616aacf4f… |
Observed Orange Book patent history#
| Captured | Edition | Application-product | Patent | Expiration | Use code | Coverage / status | Submission date | Source SHA-256 |
|---|---|---|---|---|---|---|---|---|
| 2026-09-14 22:38:34 | 2026-08 | N021137-003 | 10231931 | 2038-03-23 | Drug product | 2022-01-07 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N021137-003 | 10406108 | 2038-03-23 | Drug product | 2022-01-07 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N021137-004 | 10231931 | 2038-03-23 | Drug product | 2022-01-07 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N021137-004 | 10406108 | 2038-03-23 | Drug product | 2022-01-07 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N021137-005 | 10231931 | 2038-03-23 | Drug product | 2022-01-07 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N021137-005 | 10406108 | 2038-03-23 | Drug product | 2022-01-07 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N021137-006 | 10231931 | 2038-03-23 | Drug product | 2022-01-07 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N021137-006 | 10406108 | 2038-03-23 | Drug product | 2022-01-07 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N021137-007 | 10231931 | 2038-03-23 | Drug product | 2022-01-07 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N021137-007 | 10406108 | 2038-03-23 | Drug product | 2022-01-07 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N021137-008 | 10231931 | 2038-03-23 | Drug product | 2022-01-07 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N021137-008 | 10406108 | 2038-03-23 | Drug product | 2022-01-07 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N021137-009 | 10231931 | 2038-03-23 | Drug product | 2022-01-07 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N021137-009 | 10406108 | 2038-03-23 | Drug product | 2022-01-07 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N021137-010 | 10231931 | 2038-03-23 | Drug product | 2022-01-07 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N021137-010 | 10406108 | 2038-03-23 | Drug product | 2022-01-07 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N021137-011 | 10231931 | 2038-03-23 | Drug product | 2022-01-07 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N021137-011 | 10406108 | 2038-03-23 | Drug product | 2022-01-07 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N021137-012 | 10231931 | 2038-03-23 | Drug product | 2022-01-07 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N021137-012 | 10406108 | 2038-03-23 | Drug product | 2022-01-07 | 84e616aacf4f… | |
| 2026-08-18 06:07:40 | 2026-07 | N021137-003 | 10231931 | 2038-03-23 | Drug product | 2022-01-07 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | N021137-003 | 10406108 | 2038-03-23 | Drug product | 2022-01-07 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | N021137-004 | 10231931 | 2038-03-23 | Drug product | 2022-01-07 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | N021137-004 | 10406108 | 2038-03-23 | Drug product | 2022-01-07 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | N021137-005 | 10231931 | 2038-03-23 | Drug product | 2022-01-07 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | N021137-005 | 10406108 | 2038-03-23 | Drug product | 2022-01-07 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | N021137-006 | 10231931 | 2038-03-23 | Drug product | 2022-01-07 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | N021137-006 | 10406108 | 2038-03-23 | Drug product | 2022-01-07 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | N021137-007 | 10231931 | 2038-03-23 | Drug product | 2022-01-07 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | N021137-007 | 10406108 | 2038-03-23 | Drug product | 2022-01-07 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | N021137-008 | 10231931 | 2038-03-23 | Drug product | 2022-01-07 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | N021137-008 | 10406108 | 2038-03-23 | Drug product | 2022-01-07 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | N021137-009 | 10231931 | 2038-03-23 | Drug product | 2022-01-07 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | N021137-009 | 10406108 | 2038-03-23 | Drug product | 2022-01-07 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | N021137-010 | 10231931 | 2038-03-23 | Drug product | 2022-01-07 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | N021137-010 | 10406108 | 2038-03-23 | Drug product | 2022-01-07 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | N021137-011 | 10231931 | 2038-03-23 | Drug product | 2022-01-07 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | N021137-011 | 10406108 | 2038-03-23 | Drug product | 2022-01-07 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | N021137-012 | 10231931 | 2038-03-23 | Drug product | 2022-01-07 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | N021137-012 | 10406108 | 2038-03-23 | Drug product | 2022-01-07 | caaa826d4ba7… |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| LEVOTHYROXINE SODIUM | LEVOTHYROXINE SODIUM | A-S Medication Solutions | 194bc35b-ac82-4a40-bbd4-68eaff50b380 | 2025-09-05 | Boxed warning, Warnings, Adverse reactions | LEVOTHYROXINE SODIUM |
| LEVOTHYROXINE SODIUM | LEVOTHYROXINE SODIUM | A-S Medication Solutions | 37a55040-a9a2-4ff4-8463-9e1c7823d6ff | 2025-08-21 | Boxed warning, Warnings, Adverse reactions | LEVOTHYROXINE SODIUM |
| LEVOTHYROXINE SODIUM | LEVOTHYROXINE SODIUM | A-S Medication Solutions | 2e242b93-bc4f-405a-a194-1981c721ad94 | 2025-08-21 | Boxed warning, Warnings, Adverse reactions | LEVOTHYROXINE SODIUM |
| LEVOTHYROXINE SODIUM | LEVOTHYROXINE SODIUM | Preferred Pharmaceuticals Inc. | 609352a9-740f-4874-997b-60b58d0c2b8a | 2025-08-01 | Boxed warning, Warnings, Adverse reactions | LEVOTHYROXINE SODIUM |
| Levothyroxine Sodium | LEVOTHYROXINE SODIUM | Proficient Rx LP | 9e588c43-b9b5-478e-99f7-e197add3cd26 | 2025-08-01 | Boxed warning, Warnings, Adverse reactions | LEVOTHYROXINE SODIUM |
| levothyroxine sodium | LEVOTHYROXINE SODIUM | Bryant Ranch Prepack | c1b0fbad-5816-4152-ab59-05079e8c2148 | 2025-07-29 | Boxed warning, Warnings, Adverse reactions | LEVOTHYROXINE SODIUM |
| levothyroxine sodium | LEVOTHYROXINE SODIUM | Bryant Ranch Prepack | 9e3bffb9-f66e-4c73-befc-e60d769f6610 | 2025-07-29 | Boxed warning, Warnings, Adverse reactions | LEVOTHYROXINE SODIUM |
| Levothyroxine sodium | LEVOTHYROXINE SODIUM | Preferred Pharmaceuticals Inc. | 64aaeba7-1013-44a4-96fc-b876016897b3 | 2025-07-25 | Boxed warning, Warnings, Adverse reactions | LEVOTHYROXINE SODIUM |
| Levothyroxine Sodium | LEVOTHYROXINE SODIUM | Mylan Institutional Inc. | cd69c192-cd3f-47e6-b0a6-c536ffed5c4b | 2025-07-23 | Boxed warning, Warnings, Adverse reactions | LEVOTHYROXINE SODIUM |
| LEVOTHYROXINE SODIUM | LEVOTHYROXINE SODIUM | A-S Medication Solutions | cfab474d-3272-41fd-a8ec-762dd1a84fa6 | 2025-07-23 | Boxed warning, Warnings, Adverse reactions | LEVOTHYROXINE SODIUM |
| LEVOTHYROXINE SODIUM | LEVOTHYROXINE SODIUM | A-S Medication Solutions | b9a50170-ac0b-483e-9e85-1d03b12e4f7d | 2025-07-23 | Boxed warning, Warnings, Adverse reactions | LEVOTHYROXINE SODIUM |
| Levothyroxine sodium | LEVOTHYROXINE SODIUM | REMEDYREPACK INC. | 0fa2e2f5-401b-45c1-b6a5-d02f6faf509d | 2025-07-22 | Boxed warning, Warnings, Adverse reactions | LEVOTHYROXINE SODIUM |
| Levothyroxine Sodium | LEVOTHYROXINE SODIUM | Mylan Institutional Inc. | 5723c7a7-2a1d-4ab6-bf39-b2165ae781a6 | 2025-07-22 | Boxed warning, Warnings, Adverse reactions | LEVOTHYROXINE SODIUM |
| levothyroxine sodium | LEVOTHYROXINE SODIUM | Preferred Pharmaceuticals, Inc. | 398a00d0-1247-4f6f-b4c1-dade399cc417 | 2025-07-15 | Boxed warning, Warnings, Adverse reactions | LEVOTHYROXINE SODIUM |
| Levothyroxine sodium | LEVOTHYROXINE SODIUM | A-S Medication Solutions | 70d84fe0-afc4-4ef2-b4d8-f156abac3d1f | 2025-07-15 | Boxed warning, Warnings, Adverse reactions | LEVOTHYROXINE SODIUM |
| Levothyroxine sodium | LEVOTHYROXINE SODIUM | Preferred Pharmaceuticals Inc. | ff7f5eff-4c90-4aa0-8915-704f92dea8aa | 2025-07-15 | Boxed warning, Warnings, Adverse reactions | LEVOTHYROXINE SODIUM |
| levothyroxine sodium | LEVOTHYROXINE SODIUM | Preferred Pharmaceuticals Inc. | 412fc3f4-d9e0-49c5-b042-a6010aea7e5e | 2025-07-14 | Boxed warning, Warnings, Adverse reactions | LEVOTHYROXINE SODIUM |
| THYQUIDITY | LEVOTHYROXINE SODIUM | Oliva Therapeutics, LLC | 0c839877-50e4-455f-9b6c-462efb09cb96 | 2025-07-03 | Boxed warning, Warnings, Adverse reactions | LEVOTHYROXINE SODIUM |
| Levothyroxine Sodium | LEVOTHYROXINE SODIUM | Preferred Pharmaceuticals Inc. | 884f9fa1-58aa-4ff7-934f-106a0470e747 | 2025-07-03 | Boxed warning, Warnings, Adverse reactions | LEVOTHYROXINE SODIUM |
| Levothyroxine Sodium | LEVOTHYROXINE SODIUM | Major Pharmaceuticals | 333642fd-93ae-4dc0-9c83-6d6b163c1c74 | 2025-06-19 | Boxed warning, Warnings, Adverse reactions | LEVOTHYROXINE SODIUM |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.